LATAM Phenylketonuria Market Size & Outlook, 2026-2034


LATAM Phenylketonuria Market Insights

  • As highlighted in Reed Intelligence analysis, the LATAM Phenylketonuria Market, valued at USD 111.14 Million in 2025, is estimated to achieve USD 192.69 Million by 2034.
  • The market is estimated to grow at a CAGR of 6.32% spanning 2026 to 2034.
  • By market size, Enzyme Replacement Therapy led the By Treatment Type category in 2025.
  • The By Treatment Type segment led by Medication is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.

Other Key Findings


  • The global Phenylketonuria Market size saw LATAM holding a share of 8.42% in 2025.
  • United States is forecasted to account for the leading share of the global market by 2034.
  • In LATAM, Mexico is forecasted to be the fastest-expanding market, projected to reach USD 55.43 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 111.14 Million
Market Size In 2034 USD 192.69 Million
Largest segment Enzyme Replacement Therapy
Units Revenue in USD Million
CAGR 6.32% (2026-2034)
Segmnetation Covered
LATAM
  1. Brazil
  2. Mexico
  3. Argentina
  4. Colombia
  5. Chile
By Treatment Type
  1. Enzyme Replacement Therapy
  2. Gene Therapy
  3. Medication
  4. Dietary Therapy
By Diagnosis
  1. Genetic Testing
  2. Biochemical Testing
  3. Newborn Screening
By End-User
  1. Specialty Clinics
  2. Research Institutes
  3. Home Healthcare
  4. Hospitals
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends